News | July 16, 2022
Indian pharmaceutical companies to grow by 6-7% in FY2023: ICRA
ICRA expects the OPM of the sample set to moderate to 20.2% in FY2023 from 21.5% in FY2022.
ICRA expects the OPM of the sample set to moderate to 20.2% in FY2023 from 21.5% in FY2022.
Headwinds related to pricing pressures and rising raw material costs will result in some contraction in margins in Q4 FY22 and FY23
The stability is led by healthy demand in the domestic and emerging markets
Healthy growth in domestic and emerging markets is expected to support revenue growth in the next few quarters
Subscribe To Our Newsletter & Stay Updated
_256_275.jpg)